BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), unveiled new data
about the treatment of arterial calcification at the 2014 Transcatheter
Cardiovascular Therapeutics (TCT) conference in Washington D.C. Arterial
calcium is a common occurrence for the millions of patients suffering
from peripheral artery disease (PAD) and it can lead to significant
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device
company developing and commercializing innovative interventional
treatment systems for peripheral and coronary artery disease, today
reported financial results for its fiscal fourth quarter and year ended
June 30, 2014.
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live
webcast of its fiscal 2014 fourth-quarter conference call on Wednesday,
August 6, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, President
and Chief Executive Officer, and Larry Betterley, Chief Financial
Officer, will discuss the company’s results for its fiscal fourth
quarter ended June 30, 2014, and its financial outlook.
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced charitable donations totaling more
than $1 million to be granted between 2014 and 2016 to seven nonprofit
organizations that support patients with cardiovascular disease.
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today
announced the publication of a review article entitled “Identifying and
Overcoming Obstacles in Angiogenic Gene Therapy for Myocardial
Ischemia,” authored by Gabor M.
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) - On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs.
Sign-up for Sunshine Heart to Provide Clinical Updates From the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference investment picks
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.